Jim Cramer's Stop Trading: Consider Buying Celgene on Friday

NEW YORK (TheStreet) -- Shares of Celgene (CELG) are lower by roughly 4% despite the company beating on top and bottom line estimates and issuing strong guidance. 

On CNBC's "Cramer's Mad Dash" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said the biotech company's management almost always provides conservative guidance. 

"This company has a lot of earnings power. They've got a lot of new drugs," he added. 

The stock will likely be a down a couple of percentage points on Friday. If so, that's when investors should consider buying, Cramer concluded.


-- Written by Bret Kenwell in Petoskey, Mich.

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

If you liked this article you might like

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Apple Is the Tom Brady of Stocks: Cramer's 'Mad Money' Recap (Thursday 8/31/17)

Cramer: Fantasy Shmantasy -- Let's Get Real With These Stock Picks